jRCT2031230275招募中不适用
Special Drug Use-Results Survey (All-Case Surveillance) to Investigate Safety and Effectiveness in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Empaveli in the Post-Marketing Clinical Use in Japan (PEG_PNH JPN PMS)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 主要终点
- Hypersensitivity
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •All patients with PNH who received Empaveli in Japan from the date of product launch to 31 May 2028 or until the approval conditions are lifted.
排除标准
- •Not applicable.
结局指标
主要结局
Hypersensitivity
Occurrence of hypersensitivity adverse reactions
Meningococcal infection
Occurrence of meningococcal infection adverse reactions
Infections (except meningococci)
Occurrence of infections (except meningococci) adverse reactions
Serious hemolysis due to discontinuation of Empaveli
Occurrence of serious hemolysis due to discontinuation of Empaveli adverse reactions
次要结局
未报告次要终点
研究者
相似试验
招募中
Unknown
Special Drug Use-Results Survey (All-Case Surveillance) to Investigate Safety and Effectiveness in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Empaveli in the Post-Marketing Clinical Use in JapaParoxysmal nocturnal hemoglobinuriaJPRN-jRCT2031230275Shimmoto Naoki100
进行中（未招募）
不适用
Protocol Number; CAIN457L1401JPRN-jRCT2031210589Toshiya Sugimoto35
已完成
不适用
Special Drug Use-Results Survey for Long-term Use of XEPLION TRI Aqueous Suspension for IM Injection 175 mg, 263 mg, 350 mg, and 525 mg SyringeSchizophreniaJPRN-UMIN000042033Janssen Pharma990
已完成
不适用
Special Drug Use-results Survey for long-term use of Doxil injection 20mg (ovarian cancer aggravated after chemotherapy)ovarian cancer aggravated after chemotherapyJPRN-UMIN000015902Janssen Pharmaceutical K.K.500
已完成
不适用
A Study of TAK-660 in surgical procedures for people with hemophilia AHemophilia AJPRN-jRCT2031210173Contact for Clinical Trial Information17